The approval marks Venus Remedies’ strategic entry into complex generics, expanding its injectable portfolio beyond traditional formulations
MET-X, a novel metallo-beta-lactamase (MBL) inhibitor, has shown best-in-class performance in preclinical studies
Expects to unlock further opportunities in the Moldovan market, contributing anticipated sales of $300,000 in 2025 and approximately $700,000–$800,000 in 2026
Initiative aimed at enhancing workforce skills and competency in line with industry standards so as to create a talented workforce for the Fourth Industrial Revolution
Venus Remedies secures marketing authorization in Philippines
The recognition from Malaysia's NPRA, a member of PIC/S, opens doors to new global business opportunities
The authorization of bortezomib will enhance the company’s ability to deliver advanced cancer solutions in Southeast Asia
The company has been entrusted with the responsibility of supplying a wide range of essential oncology drugs
The company has now received 100% of the incentive owed to the company for the financial year 2022-23 under the PLI scheme
Ukrainian marketing approvals for paclitaxel, oxaliplatin and irinotecan mark a significant milestone in the company’s global expansion strategy
Subscribe To Our Newsletter & Stay Updated
